


IPW



I hereby certify that this correspondence is being deposited with the U.S. Postal Service with sufficient postage as First Class Mail, in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450, on the date shown below.

Dated: May 12, 2004 Signature: [Signature]  
(Jasbir Sagoo)

Docket No.: 105150-2  
(PATENT)

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

In re Patent Application of:  
Antonis S. Zervos

Application No.: 10/728,056

Confirmation No.: 7674

Filed: December 4, 2003

Art Unit: N/A

For: METHODS AND COMPOUNDS FOR  
INHIBITION OF CELL DEATH

Examiner: Not Yet Assigned

**TRANSMITTAL LETTER**

Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

Dear Sir:

Enclosed are the following documents for filing in connection with the above-referenced patent application:

1. Information Disclosure Statement (2 pages)
2. PTO/SB/08A (1 page)
3. Return Receipt postcard

Dated: May 12, 2004

Respectfully submitted,

By [Signature]  
Jasbir Sagoo, Ph.D.  
Registration No.: 51,177  
NUTTER MCCLENNEN & FISH LLP  
World Trade Center West  
155 Seaport Boulevard  
Boston, Massachusetts 02210-2604  
(617) 439-2000  
(617) 310-9000 (Fax)  
Applicant's Representative



I hereby certify that this correspondence is being deposited with the U.S. Postal Service with sufficient postage as First Class Mail, in an envelope addressed to: MS Amendment, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450, on the date shown below.

Dated: May 12, 2004

Signature: \_\_\_\_\_

(Jasbir Sagoo, Ph.D.)

Docket No.: 105150-0002  
(PATENT)

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

In re Patent Application of:  
Antonis S. Zervos

Application No.: 10/728,056

Confirmation No.: 7674

Filed: December 4, 2003

Art Unit: N/A

For: METHOD AND COMPOUNDS FOR  
INHIBITION OF CELL DEATH

Examiner: Not Yet Assigned

**INFORMATION DISCLOSURE STATEMENT (IDS)**

Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

Dear Sir:

Pursuant to 37 CFR 1.56, the attention of the Patent and Trademark Office is hereby directed to the references listed on the attached PTO/SB/08. It is respectfully requested that the information be expressly considered during the prosecution of this application, and that the references be made of record therein and appear among the "References Cited" on any patent to issue therefrom.

While the information and references disclosed in this Information Disclosure Statement may be "material" pursuant to 37 CFR 1.56, it is not intended to constitute an admission that any patent, publication or other information referred to therein is "prior art" for this invention unless specifically designated as such.

In accordance with 37 CFR 1.97(g), the filing of this Information Disclosure Statement shall not be construed to mean that a search has been made or that no other material information as defined in 37 CFR 1.56(a) exists. It is submitted that the Information Disclosure Statement is in compliance with 37 CFR 1.98 and the Examiner is respectfully requested to consider the listed references.

Application No.: 10/728,056

Docket No.: 105150-0002

The Director is hereby authorized to charge any deficiency in the fees filed, asserted to be filed or which should have been filed herewith (or with any paper hereafter filed in this application by this firm) to our Deposit Account No. 141449, under Order No. 105150-0002. A duplicate copy of this paper is enclosed.

Dated: May 12, 2004

Respectfully submitted,

By 

Jasbir Sagoo, Ph.D.

Registration No.: 51,177

NUTTER MCCLENNEN & FISH LLP

World Trade Center West

155 Seaport Boulevard


Boston, Massachusetts 02210-2604

(617) 439-2000

(617) 310-9000 (Fax)

Applicant's Representative

1326069.1



PTO/SB/08a/b (08-03)  
Approved for use through 07/31/2006. OMB 0651-0031  
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Substitute Form 1449A/B/PTO		<b>Complete if Known</b>			
<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  <i>(Use as many sheets as necessary)</i>		Application Number	10/728,056-Conf. #7674		
		Filing Date	December 4, 2003		
		First Named Inventor	Antonis S. Zervos		
		Art Unit	N/A		
		Examiner Name	Not Yet Assigned		
Sheet	1	of	1	Attorney Docket Number	105150-0002

U.S. PATENT DOCUMENTS					
Examiner Initials*	Cite No. <sup>1</sup>	Document Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number-Kind Code <sup>2</sup> (if known)			
	AA	US-6,004,794	12-21-1999	Karran et al.	
	AB	US-6,245,773	06-12-2001	Wong et al.	
	AC	US-2002/0010186	01-24-2002	Wong et al.	
	AD	US-2003/0073629	04-17-2003	Alnemri	

FOREIGN PATENT DOCUMENTS						
Examiner Initials*	Cite No. <sup>1</sup>	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T <sup>6</sup>
		Country Code <sup>3</sup> -Number <sup>4</sup> -Kind Code <sup>5</sup> (if known)				

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. <sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> See Kinds Codes of USPTO Patent Documents at [www.uspto.gov](http://www.uspto.gov) or MPEP 901.04. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. <sup>6</sup> Applicant is to place a check mark here if English language Translation is attached.

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
	CA	M. DAEMEN et al. "Inhibition of apoptosis induced by ischemia-reperfusion prevents inflammation," The Journal of Clinical Investigation, Volume 104, No. 5, pp. 541-549, September 1999	
	CB	B. VAN DER WATER et al. "Cleavage of the actin-capping protein $\alpha$ -adducin at asp-asp-ser-asp <sup>633</sup> -ala by caspase-3 is preceded by its phosphorylation on serine 726 in cisplatin-induced apoptosis of renal epithelial cells," The Journal of Biological Chemistry, Volume 275, No. 33, pp. 25805-25813, August 18, 2000	
	CC	G. KAUSHAL et al. "Role and regulation of activation of caspases in cisplatin-induced injury to renal tubular epithelial cells," Kidney International, Volume 60, pp. 1726-1736, 2001	
	CD	M. DAEMEN et al. "Activated caspase-1 is not a central mediator of inflammation in the course of ischemia-reperfusion," Transplantation, Volume 71, No. 6, pp. 778-784, March 27, 2001	
	CE	L. FACCIO et al. "Characterization of a novel human serine protease that has extensive homology to a bacterial heat shock endoprotease HtrA and is regulated by kidney ischemia," The Journal of Biological Chemistry, Volume 275, No. 4, pp. 2581-2588, January 28, 2000	
	CF	J. Jones et al., "Loss of Omi Mitochondrial Protease activity causes the neuromuscular disorder of mnd2 mutant mice," Nature, Volume 425 (6959), PP. 721-727, October 2003	
	CG	L. Cilenti et al. "Characterization of a novel and specific inhibitor for the pro-apoptotic protease Omi/HtrA2," The Journal of Biological Chemistry, Volume 278, No. 13, pp. 11489-11494, March 28, 2003	
	CH	R. Hegde et al. "Identification of Omi/HtrA2 as a mitochondrial apoptotic serine protease that disrupts inhibitor of apoptosis protein-caspase interaction," The Journal of Biological Chemistry, Volume 277, No. 1, pp. 432-438, January 4, 2002	

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--



Application No. (if known): 10/728,056


Attorney Docket No.: 105150-0002

## Certificate of Mailing Under 37 CFR 1.8

I hereby certify that this correspondence is being deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to:

Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

on: May 12, 2004  
Date



Signature

Jasbir Sagoo, Ph.D.

Typed or printed name of person signing Certificate

Note: Each paper must have its own certificate of mailing, or this certificate must identify each submitted paper.

IDS (Citation) by Applicant

1326065.1